Semax is a synthetic heptapeptide derived from the ACTH(4–7) sequence with an added Pro-Gly-Pro extension that improves stability. It is one of the few research peptides studied in clinical contexts, having been approved in Russia for stroke and cognitive impairment.
Russian clinical literature describes Semax use in ischemic stroke and attention disorders. Western preclinical research focuses on BDNF upregulation, neuroprotective effects in hypoxia models, and potential cognitive enhancement mechanisms.
Research Strengths
Existing human literature (Russia)
Nasal administration studied
Clear BDNF upregulation mechanism
Interesting neuroprotective profile
Limitations & Considerations
Very short half-life
Light and heat sensitive
Limited Western clinical data
This information is for research reference only. Semax is a Research Use Only (RUO) compound not approved for human or veterinary use. This does not constitute medical advice.